Front Row Advisors’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-66
| Closed | -$9.09K | – | 726 |
|
|
2024
Q2 | $9.09K | Sell |
66
-10
| -13% | -$1.38K | ﹤0.01% | 606 |
|
|
2024
Q1 | $10.5K | Buy |
+76
| New | +$10.5K | ﹤0.01% | 575 |
|
|
2023
Q4 | – | Sell |
-65
| Closed | -$7.31K | – | 693 |
|
|
2023
Q3 | $7.31K | Sell |
65
-1
| -2% | -$113 | ﹤0.01% | 589 |
|
|
2023
Q2 | $6K | Hold |
66
| – | – | ﹤0.01% | 640 |
|
|
2023
Q1 | $7K | Sell |
66
-1
| -1% | -$106 | ﹤0.01% | 605 |
|
|
2022
Q4 | $8K | Buy |
67
+6
| +10% | +$716 | ﹤0.01% | 549 |
|
|
2022
Q3 | $7K | Sell |
61
-16
| -21% | -$1.84K | ﹤0.01% | 578 |
|
|
2022
Q2 | $8K | Buy |
77
+8
| +12% | +$831 | ﹤0.01% | 558 |
|
|
2022
Q1 | $6K | Buy |
69
+18
| +35% | +$1.57K | ﹤0.01% | 676 |
|
|
2021
Q4 | $4K | Hold |
51
| – | – | ﹤0.01% | 797 |
|
|
2021
Q3 | $5K | Hold |
51
| – | – | ﹤0.01% | 746 |
|
|
2021
Q2 | $5K | Hold |
51
| – | – | ﹤0.01% | 747 |
|
|
2021
Q1 | $5K | Sell |
51
-6
| -11% | -$588 | ﹤0.01% | 736 |
|
|
2020
Q4 | $5K | Hold |
57
| – | – | ﹤0.01% | 693 |
|
|
2020
Q3 | $5K | Sell |
57
-5
| -8% | -$439 | ﹤0.01% | 693 |
|
|
2020
Q2 | $8K | Hold |
62
| – | – | 0.01% | 526 |
|
|
2020
Q1 | $6K | Buy |
62
+9
| +17% | +$871 | ﹤0.01% | 586 |
|
|
2019
Q4 | $6K | Hold |
53
| – | – | ﹤0.01% | 580 |
|
|
2019
Q3 | $5K | Buy |
53
+13
| +33% | +$1.23K | ﹤0.01% | 607 |
|
|
2019
Q2 | $3K | Hold |
40
| – | – | ﹤0.01% | 752 |
|
|
2019
Q1 | $4K | Hold |
40
| – | – | ﹤0.01% | 653 |
|
|
2018
Q4 | $3K | Buy |
40
+26
| +186% | +$1.95K | ﹤0.01% | 696 |
|
|
2018
Q3 | $1 | Buy |
+14
| New | +$1 | ﹤0.01% | 916 |
|